^
    Back
    Association details:
    Biomarker:PTBP1 underexpression
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Dis Markers
    Title:

    Abnormal PTBP1 Expression Sustains the Disease Progression of Multiple Myeloma

    Published date:
    06/18/2020
    Excerpt:
    Furthermore, Figure 3(c) shows that significantly more patients in the PTBP1low group had a higher bortezomib-treated response rate (54.1% vs. 40.1%, p = 0.03).
    DOI:
    10.1155/2020/4013658